胰腺神经内分泌肿瘤细针穿刺可可靠检测端粒替代延长及ATRX/DAXX缺失
该研究评估了胰腺神经内分泌肿瘤(PanNET)细针穿刺(FNA)标本中端粒替代延长(ALT)及ATRX/DAXX缺失的检测可行性。在65例FNA标本中,23%检出ALT,ALT阳性与更大的影像学尺寸和更高分级相关,且21例配对手术标本显示100%一致性。结论认为,在材料充足的FNA标本上可准确检测ALT和ATRX/DAXX缺失。
要点
- FNA标本可准确检测PanNET的ALT和ATRX/DAXX缺失,与手术标本100%一致。
- ALT阳性肿瘤平均影像学尺寸更大(4.9 vs 2.4 cm)且分级更高。
- 部分ALT阳性肿瘤(3/14,21%)无ATRX或DAXX核表达缺失。
核心结论
- 在材料充足的FNA标本上可准确检测ALT和ATRX/DAXX缺失,且与手术标本高度一致。
研究设计与样本
- 回顾性队列研究,纳入2005-2016年术前FNA细胞学标本65例,其中21例有配对手术切除标本。
- 采用端粒特异性荧光原位杂交检测ALT,免疫组化检测ATRX和DAXX蛋白表达。
主要发现
- 65例FNA中15例(23%)检出ALT。
- 所有ATRX阴性或DAXX阴性肿瘤均为ALT阳性,但14例ALT阳性肿瘤中3例(21%)无ATRX或DAXX核表达缺失。
- ALT阳性肿瘤与更大的影像学尺寸相关(平均4.9 vs 2.4 cm,P < .05)且分级更高(P < .05)。
- 21例配对标本中ALT状态和ATRX/DAXX免疫组化结果一致性为100%。
临床怎么用
- 对PanNET的FNA标本可开展ALT和ATRX/DAXX检测,辅助风险分层和临床试验设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pancreatic neuroendocrine tumors (PanNETs) frequently use the alternative lengthening of telomeres (ALT) pathway for telomere maintenance. ALT is strongly correlated with α thalassemia-mental retardation, X linked (ATRX), and death domain-associated protein 6 (DAXX) alterations and a poor prognosis in patients with primary PanNET. Because fine-needle aspiration (FNA) is a noninvasive way to sample tumors, the authors evaluated whether they could accurately detect ALT and loss of ATRX/DAXX in a primary PanNET cohort of FNAs. METHODS: All preoperative FNA cytology cases (2005-2016) with adequate remnant FNA cell block material were assessed for ALT by telomere-specific fluorescence in situ hybridization and for ATRX and DAXX protein expression by immunohistochemistry. For 21 patients who underwent tumor resection, the resected specimen also was assessed to determine the concordance between the FNA and surgical specimens. RESULTS: In the primary PanNET cohort of 65 FNAs, ALT was detected in 15 specimens (23%). Although all ATRX-negative and DAXX-negative tumors were ALT-positive, 3 of 14 (21%) ALT-positive tumors did not exhibit nuclear loss of either ATRX or DAXX. The ALT-positive tumors were associated with larger radiographic size (4.9 vs 2.4 cm, on average; P < .05) and higher grade (P < .05). Overall, there was 100% concordance in ALT status and ATRX/DAXX immunohistochemistry results between the FNA and surgical specimens. CONCLUSIONS: Both ALT and loss of ATRX/DAXX can be accurately performed on FNA specimens with adequate material. Because ALT is a fundamental mechanism of pathogenesis, the ability to determine ALT in small biospecimens has implications for the design of clinical trials. Cancer Cytopathol 2017;125:544-51. © 2017 American Cancer Society.
引用
- VandenBussche CJ, Allison DB, Graham MK, et al. Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors. Cancer Cytopathol. 2017. PMID: 28371511. doi:10.1002/cncy.21857
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。